Matches in SemOpenAlex for { <https://semopenalex.org/work/W2556917279> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2556917279 endingPage "5370" @default.
- W2556917279 startingPage "5370" @default.
- W2556917279 abstract "Abstract Introduction: AM3(Inmunoferon®), is a glycoconjugate of natural origin with immunomodulatory properties indicated in secondary immnunodeficiencies as well as coadjuvant treatment in neoplastic diseases with cellular immunity deficiency. Aim: To evaluate the influence of AM3 in the biological recovery of immune system in patients undergoing hematopoietic stem cells transplantation (HSCT)(autologous/allogenic). As well as to register the clinical incidences as intercurrent infections and mucositis from day of infusion hematopoietic cells to 90 days postransplantion in patients with and without AM3. Patients and methods: Group A (cases): Inclusion of 19 consecutive patients undergoing HSCT. April 2004 - June 2005. Inclusion criteria: age ≥ 18 years, first HSCT. and signed consent form. AM3 dose: 20mg/8h orally since infusion day to 90 days postransplantation. Group B (controls): 19 patients consecutively undergoing HSCT. from February 2003- March 2004. Biological evaluation of the immune system recovery: BCC, immunoproteins quantification: IgG, IgA, IgM, C3, C4, lymphoid populations distribution and activity of monocyte biomarkers (chitotriosidase, CCL18/PARC) on days −7, 0,+7,+14,+21,+28,+56,+90. Clinical evaluation and comparing cases/controls of incidence of mucositis severity evaluated according to WHO classification and microbiological documented infectious diseases. Results: The addition of AM3 as coadjuvant therapy in patients undergoing HSCT reduce significantly the percentage of oral mucositis (63.1% vs 89.5%) (p= 0.025) being those mucositis of less complexity in the first 2 weeks postransplantation. The number of infectious diseases was lower in patients under AM3 therapy (31.5% vs 47.4%) (p= 0.254) (Detailed in table). The recovery of the immune system evaluated by blood cells counts and immunobiomarkers showed a initial recuperation at day +14 in autologous HSCT and at day 21 for allogenic HSCT. The tolerance was satisfactory and only two patients needed discontinue therapy because of digestive intolerance. Wide studies must be performed in order to evaluate the benefit of this coadjuvant therapy. The inclusion of AM3 as a coadjuvant therapy in patients undergoing HSCT is associated with a significant minor percentage of oral mucositis. This work has been partially sponsored by a grant from FEHHA. Group A Group B Mean age (range) 44 (18–67) 48 (18–68) Females (%) 6 (31%) 7 (36,8%) Allogenic HSCT (M/F) 4 (21%) (3M/1F) 6 (31,5%) (5M/1F) Autologous HSCT(M/F) 15 (78,9%) (10H/5M) 13(68,4%) (7M/6F) Diagnosis Acute leukemia: 7 (37%), MM 7 (37%), MDS 2 (10%), Hodgkin disease 2nd remission 2 (11%), lymphoblastic lymphoma 1 (5%) Acute leukemia 4 (21%), MM 9 (47%), Hodgkin disease 2nd remission 2 (11%), NHL 4 (21%) Mucositis 12 (63%). Grade I: 1 patient (9%); grade II: 4 (33%); grade III: 4 (33%) 17 (89.5%). Grade II: 1 patient (6%); grade III: 6 (35%); grade IV: 9 (53%) Infectious diseases 6 (31,5%): S. Epidermidis 4 (21%), S. hominis 1 (5%), CMV 2 (10,5%), C. Albicans 1 (5%) 8 (42%): S. coagulase negative 7 (36,8%), S. viridans 1 (5.2%), S. epidermidis 1 (5.2%), Acinetobacter junii 1 (5.2%), Ochrobactrum anthropi 1 (5.2%), P. aeruginosa 1 (5.2%), C. difficile 1 (5.2%), ADN Herpes virus 6: 2 (10.5%), CMV 3 (15.7%), C. albicans 2 (10.5%), C. Krusei 1 (5.2%), P. carinii 1 (5.2%)" @default.
- W2556917279 created "2016-11-30" @default.
- W2556917279 creator A5040387233 @default.
- W2556917279 creator A5041253423 @default.
- W2556917279 creator A5052671501 @default.
- W2556917279 creator A5053795176 @default.
- W2556917279 creator A5058605172 @default.
- W2556917279 creator A5067038598 @default.
- W2556917279 creator A5073093146 @default.
- W2556917279 creator A5074713486 @default.
- W2556917279 date "2005-11-16" @default.
- W2556917279 modified "2023-09-30" @default.
- W2556917279 title "Preliminary Results of Therapy with AM3 in Patients Undergoing Hematopoietic Stem Cell Transplantation." @default.
- W2556917279 doi "https://doi.org/10.1182/blood.v106.11.5370.5370" @default.
- W2556917279 hasPublicationYear "2005" @default.
- W2556917279 type Work @default.
- W2556917279 sameAs 2556917279 @default.
- W2556917279 citedByCount "0" @default.
- W2556917279 crossrefType "journal-article" @default.
- W2556917279 hasAuthorship W2556917279A5040387233 @default.
- W2556917279 hasAuthorship W2556917279A5041253423 @default.
- W2556917279 hasAuthorship W2556917279A5052671501 @default.
- W2556917279 hasAuthorship W2556917279A5053795176 @default.
- W2556917279 hasAuthorship W2556917279A5058605172 @default.
- W2556917279 hasAuthorship W2556917279A5067038598 @default.
- W2556917279 hasAuthorship W2556917279A5073093146 @default.
- W2556917279 hasAuthorship W2556917279A5074713486 @default.
- W2556917279 hasConcept C126322002 @default.
- W2556917279 hasConcept C194409129 @default.
- W2556917279 hasConcept C203014093 @default.
- W2556917279 hasConcept C2776694085 @default.
- W2556917279 hasConcept C2777408962 @default.
- W2556917279 hasConcept C2778496288 @default.
- W2556917279 hasConcept C28328180 @default.
- W2556917279 hasConcept C2911091166 @default.
- W2556917279 hasConcept C54355233 @default.
- W2556917279 hasConcept C71924100 @default.
- W2556917279 hasConcept C86803240 @default.
- W2556917279 hasConcept C8891405 @default.
- W2556917279 hasConcept C90924648 @default.
- W2556917279 hasConceptScore W2556917279C126322002 @default.
- W2556917279 hasConceptScore W2556917279C194409129 @default.
- W2556917279 hasConceptScore W2556917279C203014093 @default.
- W2556917279 hasConceptScore W2556917279C2776694085 @default.
- W2556917279 hasConceptScore W2556917279C2777408962 @default.
- W2556917279 hasConceptScore W2556917279C2778496288 @default.
- W2556917279 hasConceptScore W2556917279C28328180 @default.
- W2556917279 hasConceptScore W2556917279C2911091166 @default.
- W2556917279 hasConceptScore W2556917279C54355233 @default.
- W2556917279 hasConceptScore W2556917279C71924100 @default.
- W2556917279 hasConceptScore W2556917279C86803240 @default.
- W2556917279 hasConceptScore W2556917279C8891405 @default.
- W2556917279 hasConceptScore W2556917279C90924648 @default.
- W2556917279 hasIssue "11" @default.
- W2556917279 hasLocation W25569172791 @default.
- W2556917279 hasOpenAccess W2556917279 @default.
- W2556917279 hasPrimaryLocation W25569172791 @default.
- W2556917279 hasRelatedWork W2024342750 @default.
- W2556917279 hasRelatedWork W2185033940 @default.
- W2556917279 hasRelatedWork W2319149848 @default.
- W2556917279 hasRelatedWork W2405611566 @default.
- W2556917279 hasRelatedWork W2775103135 @default.
- W2556917279 hasRelatedWork W2983332991 @default.
- W2556917279 hasRelatedWork W3028852703 @default.
- W2556917279 hasRelatedWork W3029997219 @default.
- W2556917279 hasRelatedWork W3030270997 @default.
- W2556917279 hasRelatedWork W3169113476 @default.
- W2556917279 hasVolume "106" @default.
- W2556917279 isParatext "false" @default.
- W2556917279 isRetracted "false" @default.
- W2556917279 magId "2556917279" @default.
- W2556917279 workType "article" @default.